RE:RE:RE:RE:RE:Strong volume - big interest early mMrMugsy wrote: EbbFlow88 wrote: I calculated cash and equivalents at around $3/share. So, you're getting GBT at $2. There is definitely weakness in currency exchange but I agree regarding value. Just will need to be patient with this one. At this price though, it's a great bet.
----------
I even throw the Other Financial Assets in there - as they are making money.
$539M CAD in cash and investments or $4.50 per share
I look at the difference in Receivable/Payables and see it covers the outstanding loan for GBT - if they can optimize and get the difference back into cash.
Roughly paying 50 cents per share for ROW.
Once we get out of COVID and people are heading back to the Dr. offices (revenue growth becomes a driver) ... then this looks cheap (at some point).
Gotta have thick skin here (IMO).
Exactly. GUD has:
Cash and equivalents: $218M
Marketable securities: $159M
Notice of reassessment: $41M
Loans outstanding: $38M
Strategic fund investments: $130M
That's around $586M, and with 130M shares outstanding, comes down to $4.50 per share. Sure, the reassessment is not a sure thing, so the expected value of that is somewhat lower than $41M. But in any case, that's "only" the Corporate segment of GUD...
... which leaves the price of $.50, or roughly $65M, for the International and Canada segments. Through Q1-Q3/2020, the International segment made $26M in adjusted earnings, includes 10 outstanding submissions and 26 drugs in the launch phase ("product has been on the market under 5 years") in the LATAM,